Austria

Authorized but outside routine outpatient reimbursement: inpatient treatment is funded through hospital financing (LKF), while outpatient coverage needs case-by-case approval by the sickness fund’s chief physician (chefärztliche Bewilligung). Vienna has a real private market (incl. published fee schedules); the Wahlarzt system refunds part of private fees — ask for a written cost breakdown first.

Off-label esketamine/ketamine treatment at private practices is legal; AKH Wien runs a treatment-resistant depression outpatient service.

Research-only under the Suchtmittelgesetz. The Medical University of Vienna is recruiting for a psilocybin study in depression with anhedonia (NCT07490353).

Research-only; no Austrian MDMA trial is recruiting.

No cannabis flower: the legal pathway is dronabinol (THC) via magistral prescription plus the authorized medicines Sativex and Canemes — parliament rejected broader liberalization in 2019. Recreational: illegal; personal-use cases are routinely diverted to health measures.

14 studies tracked, 5 active — Vienna (MedUni) plus Innsbruck (INTENSIFY site). Participation is free; screening is strict; never pay for “trial access”.